By John Q. Hosedrinker 
President Donald Trump purchased hundreds of thousands of dollars of Abbott Laboratories stock in late September of last year. This investment occurred approximately two months before the Department of Justice, under his administration, dropped a long-standing criminal investigation into the company. The investigation was examining alleged misconduct related to infant hospitalizations and deaths linked to one of Abbott’s baby formula factories, despite prosecutors reportedly believing they had evidence for criminal charges. Abbott had previously donated $500,000 to Trump’s inaugural fund, and the company later reached a settlement to resolve a related civil lawsuit alleging failures in manufacturing standards and a “culture of concealment.”
Read the original article here
It’s quite striking when we look at the timing of certain financial maneuvers and official actions, isn’t it? In this particular instance, we’re talking about former President Trump making significant investments in Abbott Laboratories stock. These purchases, totaling hundreds of thousands of dollars, happened in late September of last year, according to his financial disclosure report.
What makes these trades particularly noteworthy is what occurred shortly thereafter. The Justice Department, under the Trump administration, decided to drop a long-standing criminal investigation into Abbott Laboratories. This investigation, which had been ongoing for some time, focused on accusations of misconduct related to infant hospitalizations and deaths that were reportedly linked to one of the company’s baby formula factories.
The timing raises a significant question: could there be a connection between Trump’s personal investments and the Justice Department’s decision to halt the probe? This isn’t a small detail; the Wall Street Journal reported that key decision-makers within the DOJ opted to shut down the investigation, even when some prosecutors felt they had sufficient evidence to pursue criminal charges against the company under laws previously used for similar offenses.
It’s the kind of situation that understandably leads to accusations of insider trading and conflicts of interest. The argument is that a president, wielding immense power, could potentially influence investigations that might impact companies in which he has a financial stake. The fact that Abbott Laboratories had also made a substantial donation to Trump’s inaugural fund only adds another layer to this complex scenario, fueling speculation about undue influence.
Some might try to defend this by suggesting that Trump’s stock portfolios were managed by an independent financial advisor. While that may be true in theory, the crucial question remains: could that advisor have been acting on indirect guidance or knowledge? The sheer proximity of the stock purchases and the shelving of the investigation makes it difficult for many to dismiss the possibility of a quid pro quo, even if it’s not explicitly stated.
The situation seems to echo historical cases, like that of Martha Stewart, who faced legal consequences for insider trading. The contrast between such past instances and the apparent lack of immediate repercussions in this case is stark, leading to frustration and a sense of disillusionment among those who believe in accountability for all, regardless of their position.
This event also highlights a broader concern about the erosion of public trust and the perception of rampant corruption. When actions that appear to be blatant conflicts of interest are met with little apparent consequence, it can foster a feeling of resignation and a belief that the system is rigged. The calls for congressional oversight and stronger ethical guidelines become louder in such moments.
The defense, when it comes, often circles back to the idea that such actions are simply astute business dealings, or that “everyone does it.” There’s also a tendency to deflect by pointing fingers at perceived wrongdoings of others, a tactic that can obscure the core issue at hand.
Ultimately, the story of Trump’s stock purchases and the dropped investigation into Abbott Laboratories presents a compelling case study in the intersection of personal financial interests and presidential power. It’s a narrative that continues to spark debate about ethics, accountability, and the integrity of governmental processes. The question of whether such actions are acceptable, or if they represent a dangerous precedent, remains a significant point of contention.